Markets

Gene therapy biotech Vascular Biogenics files for a $75 million IPO to develop its cancer treatment

Vascular Biogenics, a biotech developing gene therapies to target certain cancers and inflammatory diseases, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The Or Yehuda, Israel-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol VBLX. Vascular Biogenics initially filed confidentially on March 25, 2014. Deutsche Bank and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More